
Contrasting Myeloma Therapies for Late Relapse in Patient Declining CAR T
During a live event, Robert Orlowski, MD, PhD, and participants discussed selinexor combinations, dosing, and nausea prevention for an older patient with late relapsed multiple myeloma who declines CAR T.
Patients with relapsed/refractory multiple myeloma (RRMM) that has progressed through several lines, including a bispecific antibody, and are unable to receive chimeric antigen receptor (CAR) T-cell therapy have few options that fit older age, reduced performance status, and a wish for treatment close to home. Retreatment with a B-cell maturation antigen (BCMA)–directed agent is constrained by response data after prior BCMA therapy, and some alternatives require frequent specialist visits. Oral selinexor (Xpovio) combinations are an option, but their benefit must be weighed against nausea, fatigue, and cytopenias.
In a live Case-Based Roundtable event in Houston, Texas, Robert Orlowski, MD, PhD, of The University of Texas MD Anderson Cancer Center, reviewed selinexor dosing, combination, and supportive care data and moderated discussion of an 82-year-old woman with late relapse who prefers local therapy and does not want CAR T-cell therapy. Orlowski said selinexor can be combined with many partners and is manageable with the right supportive care.
CASE SUMMARY
- An 82-year-old woman with RRMM presented to the clinic to discuss her next treatment options after several lines of therapy
- ECOG performance status (PS), 2; International Staging System (ISS) III/Revised ISS II; standard/intermediate risk cytogenetics
- She has been deemed transplant ineligible.
- She prefers to minimize time spent in the hospital and reduce the need for frequent travel to the infusion center.
- Because her commute to the academic center is over an hour each way, she would like to receive therapy closer to home.
- She would prefer not to receive CAR T.
Treatment History
- February 2024: daratumumab (Darzalex), bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Dara-VRd); complete response (CR)
- December 2024: Relapse; carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone (KPd); very good partial response (VGPR)
- March 2025: Disease progression; daratumumab and teclistamab (Tecvayli) on trial; CR
- September 2025: Relapse; talquetamab; VGPR
- January 2026: Disease progression
How would you proceed to treat this heavily pretreated patient?
EVENT RECAP
Asked how they would approach this heavily pretreated patient, 45.5% of 11 respondents chose a belantamab mafodotin (Blenrep)–based regimen, 45.5% a selinexor (Xpovio)-based regimen, and 9.1% rechallenge with a BCMA-targeted bispecific. Anirudha Dasgupta, MD, of Texas Oncology in The Woodlands, Texas, preferred to avoid belantamab because of its ocular toxicity; travel to an ophthalmologist would burden this patient.
Orlowski reviewed NCCN principles for late relapse, which favor drug classes the patient has not been exposed to, allow re-exposure if the agent was used more than 1 line earlier, allow repeating a regimen if relapse occurs at least 6 months after stopping it, and warn of lower response rates when a second BCMA-directed therapy follows immediately after the first.1
Selinexor is approved with bortezomib and dexamethasone (SVd) for patients with at least 1 prior therapy, and with dexamethasone for patients with at least 4 prior therapies whose disease is refractory to at least 2 proteasome inhibitors, 2 immunomodulatory drugs, and an anti-CD38 antibody.2 In the phase 3 BOSTON trial (NCT03110562), 195 patients with a median of 1 prior line received selinexor 100 mg once weekly with bortezomib and dexamethasone. The overall response rate (ORR) was 76%, median progression-free survival (PFS) was 13.9 months, median duration of response was 20.3 months, and median overall survival (OS) was not reached; grade 3 or higher adverse events occurred in 85% of patients and grade 5 events in 6%.3
In the phase 1b/2 STOMP trial (NCT02343042), once-weekly selinexor 40 mg (n = 28) or 60 mg (n = 20) was given with pomalidomide and dexamethasone. ORR was 50.0% vs 65.0% and median PFS was 18.4 months vs 9.5 months (HR, 0.68; 95% CI, 0.28-1.68), a descriptive comparison that was not statistically significant; any-grade nausea occurred in 32.1% vs 70.0%, and the authors concluded that the risk-benefit profile favored 40 mg.4 In 62 patients previously treated with anti-CD38 antibodies, ORR was 52.2% with selinexor, pomalidomide, and dexamethasone (n = 23), 56.3% with SVd (n = 16), and 65.2% with selinexor, carfilzomib, and dexamethasone (n = 23), and median PFS of 8.7, 6.7, and 15.0 months.5 These cohorts were small, nonrandomized, and enrolled different populations, so the regimens cannot be compared directly.
Orlowski said he starts with a lower dose of pomalidomide, "I'm not terribly convinced that [4 mg] is any better than [2 mg], and it definitely is more toxic." He said he did not expect elotuzumab (Empliciti) to add much in a patient who has been through so many regimens,
Of 10 respondents, 70% said they had used selinexor. Natalie Rafaeli, MD, of the University of Texas in Houston, said it had mostly been reserved for patients whose disease was advancing through several lines. Sara Taveras, MD, also of the University of Texas in Houston, described seeing a patient with high disease burden who only achieved stable disease but no response at 1 month on selinexor, pomalidomide, and dexamethasone. She asked if a delayed time to response would support maintaining this combination or switching. Orlowski said that where few options remain and the drug is tolerated, a patient could stay on it longer. One oncologist described stopping SVd after 6 months because of adverse events, but the patient still did well afterward.
Mohsen Arani, MD, of Texas Oncology in The Woodlands, Texas, said neutropenia required lowering selinexor from 100 mg to 80 mg and then 60 mg. Tejo N. Musunuru, MD, of MD Anderson in League City, Texas, suggested that though often used as a last resort, based on the data, selinexor may belong earlier, “as opposed to waiting until there's no other option and trying to give it at that point.” Charles Yen, MD, of Texas Oncology in Bellaire, Texas, said selinexor had been his later-line option in the past, but he would now use belantamab first.
For monitoring, Orlowski listed blood counts, chemistries, weight, nutritional status, and volume status, with hydration and calorie counseling and prophylactic antiemetics.2 NCCN antiemesis guidance includes a 5-hydroxytryptamine 3 receptor antagonist and olanzapine for prevention, with olanzapine as the preferred add-on when nausea persists despite prophylaxis.6 “I did learn the importance of premedication with nausea,” Taveras said of her experience, adding that ondansetron before each dose was enough for one patient. Musunuru said she has found olanzapine as an antiemetic may also help with taste changes and asthenia.
DISCLOSURES: Orlowski previously reported equity interest in Asylia Therapeutics; consulting fees from Amgen, Bristol Myers Squibb, Celgene, EcoR1 Capital, Forma Therapeutics, Genzyme, GlaxoSmithKline, Ionis Pharmaceuticals, Janssen, Juno Therapeutics, Kite Pharma, Legend Biotech, Molecular Partners, Sanofi, Servier, and Takeda; and research funding from Asylia Therapeutics, BioTheryX, Heidelberg Pharma AG, and Genentech.
REFERENCES
1. NCCN. Clinical Practice Guidelines in Oncology. Multiple myeloma, version 5.2026. January 9, 2026. Accessed January 27, 2026. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
2. Xpovio. Prescribing information. Karyopharm Therapeutics Inc; 2025. Accessed November 4, 2025. https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf
3. Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma: updated evidence on safety and efficacy. Front Oncol. 2025;15:1649493. doi:10.3389/fonc.2025.1649493
4. White D, Schiller GJ, Madan S, et al. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Front Oncol. 2024;14:1352281. doi:10.3389/fonc.2024.1352281
5. Schiller GJ, Lipe BC, Bahlis NJ, et al. Selinexor-based triplet regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies. Clin Lymphoma Myeloma Leuk. 2023;23(9):e286-e296.e4. doi:10.1016/j.clml.2023.06.001
6. NCCN. Clinical Practice Guidelines in Oncology. Antiemesis, version 2.2026. June 24, 2026. Accessed July 30, 2026. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
Related to this article








